The Diabetes Shared Care Program and Risks of Cardiovascular Events in Type 2 Diabetes

被引:34
|
作者
Kornelius, Edy [1 ,2 ]
Chiou, Jeng-Yuan [3 ]
Yang, Yi-Sun [1 ,2 ]
Lu, Ying-Li [1 ,2 ]
Peng, Chiung-Huei [4 ]
Huang, Chien-Ning [1 ,2 ]
机构
[1] Chung Shan Med Univ Hosp, Div Endocrinol & Metab, Dept Internal Med, Taichung, Taiwan
[2] Chung Shan Med Univ, Inst Med, Taichung, Taiwan
[3] Chung Shan Med Univ, Inst Med, Sch Hlth Policy & Management, Taichung, Taiwan
[4] Hungkuang Univ, Div Basic Med Sci, Taichung, Taiwan
来源
AMERICAN JOURNAL OF MEDICINE | 2015年 / 128卷 / 09期
关键词
Cardiovascular events; Diabetes Shared Care Program; Mortality; P4P; Taiwan; RANDOMIZED CONTROLLED-TRIAL; MELLITUS; MORTALITY; DISEASE; TAIWAN; HEMOGLOBIN; OUTCOMES; PEOPLE; ADULTS;
D O I
10.1016/j.amjmed.2015.03.025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: The Diabetes Shared Care Program (DSCP) is an integrated diabetes care model designed to increase the quality of diabetes care in Taiwan. The efficacy of this program is unknown. Therefore, we evaluated whether participating patients had reduced risks of cardiovascular events, including coronary heart disease, stroke, and all-cause mortality. METHODS: All 120,000 diabetes patients' data in this retrospective cohort study were obtained from Taiwan's National Health Insurance Research Database. DSCP participants received integrated care from a physician, diabetes educator, and dietitian. Otherwise, non-DSCP participants visited a physician without instruction from a diabetes educator or dietitian. We followed these patients until the first hospitalizations due to cardiovascular events. The Kaplan-Meier method was used to estimate the survival curves, and the Cox proportional hazards model was applied to determine the risk of cardiovascular events. RESULTS: A total of 4458 participants and 4458 matched controls were enrolled in this study. Mean age of both participants and nonparticipants was 56 years. DSCP participants had significantly lower risks of cardiovascular events (hazard ratio [HR] 0.86; 95% confidence interval [CI], 0.78-0.95), including stroke (HR 0.84; 95% CI, 0.73-0.98) and all-cause mortality (HR 0.78; 95% CI, 0.63-0.95), compared with nonparticipants. Older age, male, history of hypertension, chronic lung disease, and prescription for insulin secretagogues or insulin tended to have higher cardiovascular risks. Nevertheless, the following drugs reduced the cardiovascular risks: biguanides, alpha-glucosidase inhibitors, and thiazolidinediones. CONCLUSIONS: Participation in the DSCP was associated with lower risks of cardiovascular events, stroke, and all-cause mortality. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:977 / +
页数:12
相关论文
共 50 条
  • [1] Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes
    Paul, Sanjoy K.
    Klein, Kerenaftali
    Thorsted, Brian L.
    Wolden, Michael L.
    Khunti, Kamlesh
    CARDIOVASCULAR DIABETOLOGY, 2015, 14
  • [2] Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes
    Sanjoy K Paul
    Kerenaftali Klein
    Brian L Thorsted
    Michael L Wolden
    Kamlesh Khunti
    Cardiovascular Diabetology, 14
  • [3] Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes
    Paul, S.
    Thorsted, B. L.
    Wolden, M.
    Klein, K.
    Khunti, K.
    DIABETOLOGIA, 2013, 56 : S534 - S535
  • [4] Effect of bisphosphonates versus denosumab on risks of cardiovascular events in patients with type 2 diabetes
    Lai, Edward Chia-Cheng
    Hsieh, Miyuki Hsing-Chun
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 292 - 292
  • [5] Cardiovascular risks in type 2 diabetes and secondary cardiovascular prevention
    Ducimetière, P
    DIABETES & METABOLISM, 2005, 31 (05) : 503 - 506
  • [6] Type 2 diabetes : hypoglycaemic drugs and their cardiovascular risks
    Bauduceau, Bernard
    Bordier, Lyse
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2017, 201 (7-9): : 1209 - 1225
  • [7] Understanding cardiovascular risks in type 2 diabetes mellitus
    Chawla, Rajeev
    Trehan, Siddhant
    INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2025, 45 (01) : 3 - 4
  • [8] Canagliflozin and cardiovascular and renal events in type 2 diabetes
    Guthrie, Robert
    POSTGRADUATE MEDICINE, 2018, 130 (02) : 149 - 153
  • [9] Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
    Hinnen, Deborah
    Kruger, Davida F.
    DIABETES METABOLIC SYNDROME AND OBESITY, 2019, 12 : 447 - 454
  • [10] Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
    Fernandez-Balsells, M. Merce
    Sojo-Vega, Lidia
    Ricart-Engel, Wifredo
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (21): : 2098 - 2098